Company Overview: Editas Medicine, Inc. (NASDAQ: EDIT) is a clinical-stage gene-editing company engaged in developing transformative gene editing medicines to treat a range of serious diseases.
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms and Conditions
You are not subscribed for this report, Want to See?
US
AU
UK
CA
NZ